There are currently 66 active clinical trials seeking participants for Ulcerative Colitis research studies. The states with the highest number of trials for Ulcerative Colitis participants are Florida, California, Texas and New York.
Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
NCT05782907
Recruiting
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess how safe and effective Upadacitinib is in treating pediatric participants with UC. Adverse events and change in disease activity will be assessed. Upadacitinib (RINVOQ) is a drug approved in adults for moderate- to severely active UC and is being developed for moderate- to severely active UC in pediatric participa... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
03/17/2025
Locations: Phoenix Children's Hospital /ID# 250135, Phoenix, Arizona +82 locations
Conditions: Ulcerative Colitis
Register for Updates
Tailored Anti-Inflammatory (A-I) Diet for Hispanics with Ulcerative Colitis (UC)
NCT06784323
Recruiting
The purpose of this study is to test the effect of an anti-inflammatory diet that incorporates native foods of the Hispanics/Latino (H/L) diet on disease remission in H/L patients with Ulcerative Colitis (UC) and to identify biomarkers of response to dietary therapy.
Gender:
ALL
Ages:
Between 16 years and 75 years
Trial Updated:
03/14/2025
Locations: University of Miami Health System, Miami, Florida
Conditions: Ulcerative Colitis
Register for Updates
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
NCT06254950
Recruiting
The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems. The participants will take capsules of either TAK-279 or placebo for up to 3 months (12 weeks). Then all the participants will receive TAK-279 for the rest of the treatment part of the study (1 year or 52 weeks). During the study,... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/12/2025
Locations: GastroIntestinal BioSciences, Los Angeles, California +171 locations
Conditions: Ulcerative Colitis
Register for Updates
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
NCT06100289
Recruiting
The main aim of this study is to learn how the body of a child or teenager with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD) processes vedolizumab (pharmacokinetics) given just under the skin subcutaneously (SC). The participants will be treated with vedolizumab for up to 34 weeks. During the study, participants will visit their study clinic several times.
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
03/12/2025
Locations: VVCRD Clinical Research, Garden Grove, California +56 locations
Conditions: Ulcerative Colitis, Crohn's Disease
Register for Updates
Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC)
NCT05987852
Recruiting
Chronic intestinal hypoxia and accompanying mucosal inflammation is a hallmark of ulcerative colitis (UC). Hyperbaric oxygen therapy (HBOT) involves breathing 100% oxygen under increased atmospheric pressure to increase tissue oxygenation. Two small prospective randomized controlled trials have demonstrated that the delivery of HBOT to UC patients hospitalized for acute moderate to severe flares results in improved remission rates and avoidance of in-hospital progression to biologics, small mole... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/11/2025
Locations: University of Alabama Medicine, Birmingham, Alabama +12 locations
Conditions: Ulcerative Colitis
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)
NCT06137183
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of vixarelimab compared with placebo in participants with moderate to severe UC who have demonstrated inadequate response to, loss of response to, or intolerance to prior conventional or advanced therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: Gulf Coast Gatroenterology, Fairhope, Alabama +119 locations
Conditions: Ulcerative Colitis
Register for Updates
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06029972
Recruiting
The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with tilpisertib fosmecarbil with participants treated with placebo. The primary objective of this study is to demonstrate the efficacy of tilpisertib fosmecarbil, compared to placebo control, in achieving Clinical Response at Week 12.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/28/2025
Locations: Arizona Digestive Health, Sun City, Arizona +120 locations
Conditions: Ulcerative Colitis
Register for Updates
High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy
NCT04331639
Recruiting
The investigators will be administering oral high dose interval vitamin D, concurrently when participants are receiving biologic therapy for their inflammatory bowel disease. The investigators will be collecting some additional bloodwork and questionnaires at the time of participants infusions.
Gender:
ALL
Ages:
Between 5 years and 25 years
Trial Updated:
02/27/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis, Vitamin D Deficiency
Register for Updates
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
NCT04624230
Recruiting
This study, A3921210 is designed to evaluate the efficacy, safety and pharmacokinetics (PK) of tofacitinib in pediatric participants with moderately to severely active UC. In the US and EU, patients with prior TNFi failure or intolerance will be enrolled. Outside of the US or EU, patients having had inadequate response or intolerance to oral or IV corticosteroids or azathioprine or 6-mercaptopurine or TNFi will be enrolled. All eligible participants will initially receive open label tofacitinib... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
02/26/2025
Locations: Phoenix Children's Hospital, Phoenix, Arizona +100 locations
Conditions: Ulcerative Colitis
Register for Updates
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
NCT06598943
Recruiting
The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/26/2025
Locations: Southern California GI and Liver Centers (SCLC), Coronado, California +125 locations
Conditions: Ulcerative Colitis, Ulcerative Colitis Chronic
Register for Updates
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945
Recruiting
This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Participants who complete the 3-year study may continue to receive mirikizumab until it is (outside of this study) in their country or until they meet other discontinuation criteria.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/24/2025
Locations: Digestive Health Specialists, Dothan, Alabama +366 locations
Conditions: Ulcerative Colitis
Register for Updates
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
NCT05784246
Recruiting
The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC).
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
02/24/2025
Locations: Rady Children's Hospital- San Diego, San Diego, California +55 locations
Conditions: Ulcerative Colitis
Register for Updates